Amisulpride, an unusual "atypical" antipsychotic: A meta-analysis of randomized controlled trials

American Journal of Psychiatry

Volumn 159, Issue 2, 2002, Pages 180-190

  Leucht, Stefan ^a   Pitschel Walz, Gabi ^a   Engel, Rolf R ^a   Kissling, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE; TREATMENT OUTCOME;

EID: 0036161972     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.2.180     Document Type: Review

References (64)

1. The role of serotonin in schizophrenia
2. New dimensions in the pharmacologic treatment of schizophrenia and related psychoses
3. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
4. Negative symptoms in schizophrenia: Considerations for clinical trials
5. Treatment of negative symptoms in schizophrenia with amisulpride
6. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
7. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
8. Clinical update on amisulpride in deficit schizophrenia
9. 3 dopamine receptor antagonist activity and limbic selectivity
10. Amisulpride: From animal pharmacology to therapeutic action
11. The brief psychiatric rating scale
12. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and theoretical foundations
13. A simple general purpose display of magnitude of experimental effect
14. Meta-analysis in clinical trials
15. Therapievergleich von aminosultoprid (DAN 2163) und perazin bei schizophrenen patienten
16. Etude multicentrique controlée en double insu, amisulpride (Solian 200) versus halopéridol à forte dose dans les états psychotiques aigus
17. Study of the efficacy of a substituted benzamide amisulpride, versus haloperidol, in productive schizophrenia
18. A double-blind comparison of amisulpride vs haloperidol in acute schizophrenic patients
19. Comparative double-blind study of amisulpride versus haloperidol in the treatment of acute psychotic states
20. Amisulpride versus haloperidol in treatment of schizophrenic patients - Results of a double-blind study
21. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol
22. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - A double-blind controlled study comparing a selective D-2-like antagonist to a mixed D-1-/D-2-like antagonist
23. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs haloperidol
24. Amisulpride has superior benefit/risk profile to haloperidol in schizophrenia: Results of a multicentre, double-blind study
25. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
26. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
27. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms - Amisulpride v haloperidol
28. Controlled double-blind multi-centre trial of low dose amisulpride versus fluphenazine in the treatment of the negative syndrome of chronic schizophrenia
29. Clinical, EEG mapping and psychometric studies in negative schizophrenia: Comparative trials with amisulpride and fluphenazine
30. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia
31. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
32. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: A double-blind randomized controlled trial
33. The relationship between negative symptoms of schizophrenia and extrapyramidal side-effects with haloperidol and olanzapine
34. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, "Seroquel") and haloperidol in schizophrenia
35. Risperidone versus haloperidol on secondary memory: Can newer medications aid learning?
36. A study of enhanced management in patients with treatment-resistant schizophrenia
37. Risperidone in treatment-refractory schizophrenia
38. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study
39. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: A double-blind randomized controlled trial
40. Antipsychotic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients
41. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol
42. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia
43. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
44. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials
45. What is an atypical antipsychotic?
46. Aktuelle bewertung neuer/atypischer neuroleptika
47. A path-analytical approach to differentiate between direct and indirect effects on negative symptoms in schizophrenia: A re-evaluation of the North American risperidone study
48. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
49. Direct effect of sertindole on the primary negative symptoms of schizophrenia: A PATH analysis
50. Clinical trial of quetiapine in schizophrenia - Efficacy and tolerability of quetiapine: A comparative double-blind study with mosapramine in schizophrenic patients
51. Safety of amisulpride (Solian): A review of 11 clinical studies
52. Antipsychotic-induced weight gain: A comprehensive research synthesis
53. Atypical antipsychotics and weight gain - A systematic review
54. Dropout rates in randomised antipsychotic drug trials
55. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
56. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
57. Olanzapine: A basic science update
58. Seroquel: Electrophysiological profile of a potential atypical antipsychotic
59. D4 dopamine antagonist group: The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia
60. Will new dopamine receptors offer a key to schizophrenia?
61. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia
62. BIMG 80, a novel potential antipsychotic drug: Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex